12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tirasemtiv: Completed Phase IIb enrollment

Cytokinetics completed enrollment of over 700 patients in the international Phase IIb BENEFIT-ALS trial of twice-daily oral tirasemtiv. Patients will receive 125 mg tirasemtiv in a 1-week, open-label period, which will be followed by a 12-week, double-blind, placebo-controlled period evaluating ascending doses of tirasemtiv starting at 125 mg...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >